Research presented at the European Congress on Obesity in 2024, for instance, found that people who gradually reduced their dose to zero (over an average of nine weeks) maintained a stable body weight in the first 26 weeks after tapering
Evaluation of the glucocorticoid receptor as a biomarker of treatment response in Vogt-Koyanagi-Harada disease
(2025) HCG-Based Clinical Treatments for Infertile Men with Non-Obstructive Azoospermia Andrology
Over the course of this interview, she shares how she evaluates peptides, why gut function is foundational to hormone optimization, how she approaches GLP1 microdosing, and what she watches for in long-term care
The renal lesions of Alport syndrome
Iwasaki Y, Goswami C, Yada T